Dr Reddy's Laboratories Financials - Benzinga

Dr Reddy's Laboratories Ltd

RDYNYSE

Trade with Public

Trade with Public

$12.13

-0.05-0.41%

At close: Aug 28, 5:00 PM EST

$12.18

N/A

Pre-Market: 4:44 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Dividends Compare Options Stock Report

Dr Reddy's Laboratories Financials

Dr Reddy's Laboratories (RDY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat

Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutide issues & Trump tariff plans weigh on shares.

Vandana Singh

PRO
Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M Estimate

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.17 by 64.71 percent. This is a 70 percent decrease over earnings of $0.20 per share

Benzinga Newsdesk

Earnings Scheduled For July 22, 2026

Companies Reporting Before The Bell • Northern Trust (NASDAQ:NTRS) is expected to report quarterly earnings at $3.45 per share on revenue of $2.35 billion. • Old National Bancorp (NASDAQ:ONB) is projected to report

Benzinga Insights

PRO
Dr Reddy's Laboratories Q4 EPS $0.03 Misses $0.09 Estimate, Sales $821.821M Miss $866.120M Estimate

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.09 by 66.67 percent. This is a 86.36 percent decrease over earnings of $0.22 per share

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Dr Reddy's Laboratories Q3 EPS $0.16, Inline, Sales $978.820M Beat $978.100M Estimate

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 18.5 percent decrease over earnings of $0.20 per share from the same period last year.

Benzinga Newsdesk